PositiveID Corporation Launches "The Wireless Body" at ID WORLD International Congress in Milan, Italy

Smart Healthcare Communication System Offers Patients With Diabetes a Revolutionary Disease Management Platform

DELRAY BEACH, Fla., Nov. 17, 2010 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or the "Company") (Nasdaq:PSID) announced today that it has launched "The Wireless Body™" at the ID WORLD International Congress in Milan, Italy. The "Wireless Body" is an integrated, in vivo and external, smart healthcare communication system for diabetes management today and other disease management applications in the future. The "Wireless Body" is designed to enhance the management of diabetes by allowing disease management systems to communicate with each other and deliver solutions to patients seamlessly, enhancing the ability to deliver personalized medical solutions wirelessly.

Using its experience and expertise gained from developing the world's first and only health-related implantable RFID (radio frequency identification) microchip cleared by the U.S. Food and Drug Administration, the Company has initiated the integration and development of other healthcare communication devices to communicate from within the body to outside of the body on an integrated platform: The "Wireless Body" by PositiveID. The "Wireless Body" also has the ability to identify medical devices, currently catheter ports, to allow them to communicate with PositiveID's products to ensure proper medication dosages and safety for the patient from the port.

"We are excited to launch The Wireless Body as it expands the solutions we offer patients with diabetes to an entirely new level," said Scott R. Silverman, Chairman and CEO of PositiveID. "Diabetes management requires an integrated solution, one that allows continuous monitoring and communication with devices that deliver solutions. We believe the ability to deliver an integrated solution wirelessly will enhance the quality of life for patients with diabetes and improve their compliance. The recent $24 million investment by Novartis into Proteus Biomedical's ingestible wireless microchip highlights the opportunities in this sector and clearly validates the vision we began in this field over seven years ago."

The Company's technology has previously been used in Smart Healthcare by providing a vital electronic medical record and other wellness information to patients, caregivers and physicians. Most recently, PositiveID has evolved its implantable technology to focus on sensor applications through its GlucoChip™, a glucose-sensing microchip currently under development, and potentially other sensor applications based on its Patent No. 7,125,382 for an Embedded Bio-Sensor System. The GlucoChip is designed to communicate wirelessly to a handheld scanner outside of the body to deliver in vivo glucose readings without the need to draw blood.

Moving forward, the Company plans to integrate its wireless product portfolio with its patent-pending iglucose™ system, a wireless communication system for the transmission of glucose readings, to create automatic logs of glucose readings which can be delivered wirelessly to a third party (i.e. a caregiver or physician) from a handheld reader or traditional glucometer.

About PositiveID Corporation

PositiveID Corporation develops and markets healthcare and information management products through its RFID-based diagnostic devices and identification technologies, and its proprietary disease management tools. PositiveID's implantable healthcare devices and external hardware and software products are designed to communicate wirelessly to improve healthcare and the patient's quality of life. For more information on PositiveID, please visit www.PositiveIDCorp.com.

The PositiveID Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7717

Statements about PositiveID's future expectations, including the likelihood that the Company's The Wireless Body smart healthcare communication system offers patients with diabetes a revolutionary disease management platform; the ability of The Wireless Body to enhance the management of diabetes by allowing disease management systems to communicate with each other and deliver solutions to patients seamlessly, enhancing the ability to deliver personalized medical solutions wirelessly; the likelihood that the Company will be successful in the integration and development of other healthcare communication devices to communicate from within the body to outside of the body on The Wireless Body integrated platform; the ability of The Wireless Body to identify medical devices, currently catheter ports, to allow them to communicate with PositiveID's products to ensure proper medication dosages and safety for the patient from the port; the likelihood that the ability to deliver an integrated solution wirelessly will enhance the quality of life for patients with diabetes and improve their compliance; the ability of the Company's GlucoChip, currently under development, to communicate wirelessly to a handheld scanner outside of the body to deliver in vivo glucose readings without the need to draw blood; the likelihood that the Company will integrate its wireless product portfolio with its patent-pending iglucose™ system, a wireless communication system for the transmission of glucose readings, to create automatic logs of glucose readings which can be delivered wirelessly to a third party (i.e. a caregiver or physician) from a handheld reader or traditional glucometer; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include the Company's ability to successfully develop and commercialize the iglucose system and GlucoChip, the timing and success of submission, acceptance and approval of required regulatory filings; as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 19, 2010, and the Company's 10-Qs filed on May 6, 2010, and August 13, 2010, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

http://investors.positiveidcorp.com/releasedetail.cfm?ReleaseID=531278

• Home
• Contact
• Download E-book
• Advertise
• My Colection
• Global News
• 2010

PositiveID Corporation Expands Its Wireless Body Platform Utilizing Its Patented Embedded Bio-Sensor System

Company Partners With RFID Solutions of Malaga, Spain to Develop Continuous Temperature-Sensing Microchip to Integrate With The Wireless Body(TM)

DELRAY BEACH, Fla., Nov. 29, 2010 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or the "Company") (Nasdaq:PSID) announced today that it has expanded its Wireless Body™ platform to include a new bio-sensor application for temperature. PositiveID has partnered with RFID Solutions of Malaga, Spain to develop a temperature-sensing microchip to continuously measure temperature from within the body and communicate that reading to an external scanner. The Company plans to integrate the temperature-sensing microchip with The Wireless Body, an integrated, in vivo and external, smart healthcare communication system that has the ability to deliver personalized medical solutions wirelessly.

The Wireless Body will be designed to enhance wellness and disease management, for diabetes and other chronic illnesses, by allowing healthcare systems to communicate with each other and deliver solutions to patients seamlessly. The Wireless Body can also be applied to other wellness applications such as for individuals who may require continuous monitoring of vital signs, including temperature, as a safety precaution.

The Wireless Body communication system is built on the Company's Patent No. 7,125,382 for an Embedded Bio-Sensor System. PositiveID will work with RFID Solutions, an advanced technical development group with innovative automated manufacturing and expertise in specialized requirements for sensors in RFID markets, to develop a temperature-sensing microchip for use in humans. RFID Solutions will build upon the existing technology and intellectual property portfolio of PositiveID, the creator of the world's first and only health-related implantable RFID microchip cleared by the U.S. Food and Drug Administration.

The Company expects its Wireless Body platform will continue to evolve with the addition of other vital sign-sensing capabilities. The Company is also developing a glucose-sensing microchip, as well as other devices for improved disease management, that will be integrated with The Wireless Body.  The Wireless Body also has the ability to identify medical devices, currently catheter ports, to allow them to communicate with an external reader to ensure proper medication dosages and safety for the patient.

"The ability to continuously monitor a patient's vital signs provides a real-time gauge of their health and wellness," said Scott R. Silverman. "The addition of temperature-sensing capabilities to The Wireless Body platform is just one of many applications that we intend to provide for improved patient care. As mobile health initiatives continue to grow, we have chosen a strong development partner in RFID Solutions, which, we believe, can efficiently and expertly deliver this application for us."

About PositiveID Corporation

PositiveID Corporation develops and markets healthcare and information management products through its diagnostic devices and identification technologies, and its proprietary disease management tools. PositiveID's implantable healthcare devices and external hardware and software products are designed to communicate wirelessly to improve healthcare and the patient's quality of life. For more information on PositiveID, please visit www.PositiveIDCorp.com.

The PositiveID Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7717

Statements about PositiveID's future expectations, including the Company's ability to develop a temperature-sensing microchip to continuously measure temperature from within the body and communicate that reading to an external scanner; the Company's ability to integrate the temperature-sensing microchip with The Wireless Body; the ability of The Wireless Body to enhance wellness and disease management, for diabetes and other chronic illnesses, by allowing healthcare systems to communicate with each other and deliver solutions to patients seamlessly; the likelihood that the Wireless Body can also be applied to other wellness applications such as individuals who may require continuous monitoring of vital signs, including temperature, as a safety precaution; RFID Solutions' ability to build upon the existing technology and intellectual property portfolio of PositiveID;  the likelihood that The Wireless Body platform will continue to evolve with the addition of other vital sign-sensing capabilities for improved patient care; the ability of the Company to develop a glucose-sensing microchip, as well as other devices for improved disease management, that will be integrated with The Wireless Body; the ability of The Wireless Body to identify medical devices to allow them to communicate with an external reader to ensure proper medication dosages and safety for the patient; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include the Company's ability to successfully develop and commercialize a temperature-sensing microchip and a glucose-sensing microchip, as well as The Wireless Body platform, as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 19, 2010, and the Company's 10-Qs filed on May 6, 2010, August 13, 2010, and November 12, 2010, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

http://investors.positiveidcorp.com/releasedetail.cfm?ReleaseID=533390